Are Peptides FDA Approved for Therapy?

FDA approval status splits clearly across peptide categories. Semaglutide, tirzepatide, and insulin are approved for specific indications. BPC-157, GHK-Cu, sermorelin, and most regenerative peptides used in longevity and aesthetics do not carry full approval. That doesn’t mean they’re banned. It means the evidence threshold for full approval hasn’t been met, and the legal pathway for most runs through physician prescription and compounding rather than formal drug approval.

According to Dr Harikiran Chekuri, one of India’s pioneering plastic surgeon, “FDA approval status is not the same as safe and not the same as effective. Some of the most clinically useful peptides available today sit outside full FDA approval while some approved drugs have significant risk profiles. What matters more than approval status is the quality of the clinical assessment, the sourcing, and the supervision behind any protocol.”

Different peptide categories sit in very different regulatory positions. Here’s how each one is classified.

• GLP-1 agonists are fully FDA approved: Semaglutide, tirzepatide, and liraglutide have FDA approval for type 2 diabetes and obesity management. These went through full Phase 3 clinical trial programmes. The evidence base is robust.
• Tesamorelin has approval for one specific indication: FDA-approved for excess abdominal fat in HIV patients with lipodystrophy. Off-label use for anti-ageing and body composition is widespread but sits outside that approval boundary.
• Sermorelin was approved then discontinued: Originally approved as a diagnostic agent. The manufacturer withdrew the commercial product. It remains available through compounding, which is legal but different from active FDA approval.
• BPC-157 and GHK-Cu have no FDA approval: Both are widely used clinically for tissue repair and regeneration. Neither has completed the Phase 3 trial process FDA approval requires. Available through compounding under physician prescription.
• PT-141 carries specific approval: The only FDA-approved melanocortin receptor agonist, approved for hypoactive sexual desire disorder. A rare example of a non-metabolic peptide making it through full drug approval.

Approval status and clinical usefulness are separate questions. For patients in Hyderabad, Redefine Hair Transplant and Plastic Surgery Center prescribes only pharmaceutical-grade compounds through verified clinical channels regardless of approval status.

FDA non-approval is widely misunderstood. Here’s what it actually means in practice.

• Non-approval means insufficient trial data, not proven unsafe: Most regenerative peptides lack FDA approval because large-scale human trials haven’t been completed. That’s a data gap, not a safety finding. The two are not the same thing.
• Compounding provides a legal pathway: Physician-prescribed compounded peptides sit within a legal clinical framework in both the US and India. This isn’t a workaround. It’s how most legitimate peptide clinics operate.
• In India, CDSCO approval governs legality, not the FDA: The FDA is a US regulator. In India, what matters is CDSCO classification and physician prescription status. Some compounds with no FDA approval are entirely legal and appropriate to prescribe here under Indian regulation.
• Sourcing quality matters more than approval status for safety: The practical safety risk with non-approved peptides comes from contaminated or counterfeit compounds, not from the absence of FDA paperwork. Pharmaceutical-grade sourcing through verified clinical channels addresses this directly.
• Off-label use of approved peptides is common and legal: Physicians can and do prescribe FDA-approved peptides for indications beyond their approved use. Tesamorelin for anti-ageing is one example. Legal, common, and outside the approved boundary simultaneously.

FDA approval status is worth clarifying before any peptide protocol begins. Read our previous blog on Peptide Treatment Legal to see how peptide regulation works specifically under Indian law.

Dr. Harikiran Chekuri is one of India’s pioneering surgeons offering Peptide Therapy in Hyderabad, and at Redefine every peptide protocol is built on pharmaceutical-grade sourcing, physician prescription, and clinical assessment regardless of approval status, because patient safety depends on compound quality, clinical rationale, and supervision throughout, not on approval paperwork, and that standard has held across thousands of peptide cases here.

At Redefine Hair Transplant and Plastic Surgery Center, every patient gets a straight answer on approval status, legal standing in India, and the clinical evidence behind each compound before any protocol begins.

References

• • PubMed Central: GLP-1 Receptor Agonists FDA Approval and Clinical Evidence: https://www.ncbi.nlm.nih.gov/pmc
  • NCBI Bookshelf: Semaglutide FDA Approval and Indications: https://www.ncbi.nlm.nih.gov/books/NBK603723/
  • U.S. Food and Drug Administration: Concerns with Unapproved GLP-1 Drugs: https://www.fda.gov